Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
Cstone Pharmaceuticals (HKG:2616) reported a loss for the year attributable to owners of about 367.2 million yuan, down from a loss of 902.7 yuan in the previous year, according to the annual results
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, CStone Pharmaceuticals (HKG:2616) shares are down a considerable 34% in the last month, which continues a horrid run for the company. For any long-term shareh
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
Cstone Pharmaceuticals (HKG:2616) said China's National Medical Products Administration (NMPA) approved a supplemental biologics license application (sBLA) for sugemalimab in combination with fluoropy
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
Insider Purchases Worth CN¥6.54m See Losses As CStone Pharmaceuticals Market Value Drops To HK$1.4b
The recent price decline of 31% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥6.54m worth of shares at an average price of CN¥2.52 in the past 12 months. In
CStone Pharmaceuticals Removed From Hong Kong Stock Connect; Shares Plunge 26%
CStone Pharmaceuticals (HKG:2616) has been removed from the Hong Kong Stock Connect effective March 4, a Monday filing said. The removal from the Stock Connect program comes after the company was deli
Why Investors Shouldn't Be Surprised By CStone Pharmaceuticals' (HKG:2616) 25% Share Price Plunge
The CStone Pharmaceuticals (HKG:2616) share price has softened a substantial 25% over the previous 30 days, handing back much of the gains the stock has made lately. The recent drop completes a dis
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million
CStone Pharmaceuticals (HKG:2616) arm CStone Pharmaceuticals (Suzhou) has agreed to sell its CStone Ivosidenib business to France-based pharma group Les Laboratoires Servier for $50 million. CStone an
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 16% Slide
Insiders who bought CN¥6.54m worth of CStone Pharmaceuticals' (HKG:2616) stock at an average buy price of CN¥2.52 over the last year may be disappointed by the recent 16% decrease in the stock. This
Private Equity Firms Among CStone Pharmaceuticals' (HKG:2616) Largest Stockholders and Were Hit After Last Week's 16% Price Drop
Key Insights Significant control over CStone Pharmaceuticals by private equity firms implies that the general public has more power to influence management and governance-related decisions The top 5
CStone Pharmaceuticals' H1 Loss Narrows
CStone Pharmaceuticals' (HKG:2616) loss narrowed to 210.1 million yuan, or 0.17 yuan per share, in the first half, from 361.6 million yuan, or 0.31 yuan per share, in the year-ago period, a Tuesday fi
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 15% Slide
The recent price decline of 15% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥14m worth of shares at an average price of CN¥3.45 in the past 12 months. This
China Approves CStone Pharmaceuticals' New Drug Application for Lung Cancer Treatment; Shares Rise 3%
China's medical products administrator approved CStone Pharmaceuticals' (HKG:2616) supplemental new drug application for its Gavreto treatment for non-small cell lung cancer, a Tuesday filing said. Th
CStone Pharmaceuticals CEO Boosts Shareholding
CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang purchased an additional 460,000 shares in the open market on June 19 and 20, according to a Monday filing. Yang now has 3,732,500
CStone Pharmaceuticals' Phase 3 Results of Lung Cancer Treatment Trial Published in US Medical Journal
CStone Pharmaceuticals (HKG:2616) said US medical journal Nature Cancer published the results of its overall survival analysis from its phase 3 clinical study assessing sugemalimab for first-line stag
Investors Don't See Light At End Of CStone Pharmaceuticals' (HKG:2616) Tunnel
CStone Pharmaceuticals' (HKG:2616) price-to-sales (or "P/S") ratio of 6.1x might make it look like a strong buy right now compared to the Biotechs industry in Hong Kong, where around half of the compa
CStone Pharmaceuticals Presents Data From Leukemia Treatment Study During US Oncology Meet
CStone Pharmaceuticals (HKG:2616) presented data from its phase 3 study of its combination of ivosidenib tablets and the chemotherapy azacitidine for newly-diagnosed acute myeloid leukemia at an oncol
CStone Pharmaceuticals to Regain Commercialization Rights to Cancer Treatments
08:31 PM EDT, 05/08/2023 (MT Newswires) -- CStone Pharmaceuticals (HKG:2616) will regain its development and commercialization rights to cancer treatments sugemalimab and nofazinlimab outside China fo
As CStone Pharmaceuticals (HKG:2616) Drops to HK$4.4b Market Cap, Insiders Might Rethink Their CN¥8.7m Stock Purchase Earlier This Year
Insiders who bought CN¥8.7m worth of CStone Pharmaceuticals' (HKG:2616) stock at an average buy price of CN¥4.05 over the last year may be disappointed by the recent 9.5% decrease in the stock. Insid
No Data